PARP1 and ovarian cancer: Although PARP inhibitors in the single-agent setting have demonstrated benefits in DNA-repair-deficient cancers (e.g., BRCA-mutated ovarian cancer), combinations such as rucaparib and carboplatin may be useful in a wider population, including in cancers with and without homologous repair deficiency.